As the technology for gene therapy develops in vitro and in vivo in animal models, it is becoming clear that the three principal approaches - recombinant retroviruses, recombinant adenovirus, and direct DNA delivery - will ultimately have applications in specific therapeutic situations that take full advantage of the unique features of the specific delivery system: low level persistent expression after ex vivo recombinant retroviral therapy, high level transient expression after in vivo recombinant adenoviral therapy, or moderate level transient expression after in vivo administration of a synthetic DNA complex, which in principle could be repeated as desired.
CITATION STYLE
Smith, L. C., Eisensmith, R. C., & Woo, S. L. C. (1995). Gene therapy in heart disease. Advances in Experimental Medicine and Biology. Springer New York LLC. https://doi.org/10.1007/978-1-4615-1957-7_8
Mendeley helps you to discover research relevant for your work.